Case report: Pharmacokinetics of pembrolizumab in a patient with stage IV non–small cell lung cancer after a single 200 mg administration

BACKGROUND: Pembrolizumab is a well-tolerated biologic agent with a potentially stable and durable anti-tumor response. Unfortunately, discontinuation of therapy can occur as a consequence of immune-related adverse effects (irAEs). These irAEs appear independent of dose and exposure. However, such i...

Descripción completa

Detalles Bibliográficos
Autores principales: de Vries, Fenna, Smit, Adrianus A. J., Wolbink, Gertjan, de Vries, Annick, Loeff, Floris C., Franssen, Eric J. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875126/
https://www.ncbi.nlm.nih.gov/pubmed/36713570
http://dx.doi.org/10.3389/fonc.2022.960116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875126/
https://www.ncbi.nlm.nih.gov/pubmed/36713570
http://dx.doi.org/10.3389/fonc.2022.960116

Ejemplares similares